NAS10027,908+3.40%S&P7,550+2.35%GOLD$4,133+1.43%BTC$74,900+0.42%VIX19.92−22.31%latest tape · as of 02:02 UTC
The Screen · Healthcare · Diagnostics & Research
Danaher Corporation
DHR · a US exchange · USD · Market cap $166.6B · 58,000 employees
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.30, read 2026-11-08
Ethical passes the values gate
Price230.25 USD
Fair value232.52
Ethical score88.2/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup224.49+2.6% to today ✓Accumulation gives way to Markup first Markup read since August
2026-10-02Read Accumulation224.49+2.6% to today ✓Markup gives way to Accumulation with volume flow in agreement
2026-08-22Read Markup215.91+6.6% to today ✓Markdown gives way to Markup after a 17% rise in 7 weeks
2026-07-02Read Markdown184.30+24.9% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Danaher Corporation holds its Markup at $230.25. The statistical read favours the buyers, held for 6 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 6 days
Price at the screen
$230.25
Valuation
39.24 trailing · 25.43 forward price to earnings
Values screen
PASS· score 88.2
Beta
0.80
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.60%
Below 33%
Interest-bearing debt is just 23.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
10.22%
Below 49%
Money owed to the company is 10.2% of assets, under the 49% limit.
Pass
Revenue purity
0.12%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Danaher clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-08. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DHR's ethical verdict changes
Today DHR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 1% discount to our $232.52 fair value, narrow competitive moat, 8.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 1.0% discount to the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +13% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $232.52, with a range of $198.00 to $267.40, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it is worth knowing
A quality business: a narrow moat and 17% profit margins. It trades close to our $232.52 fair value, so the easy discount is gone; you would be paying up for the quality.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DHR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$230.11-0.6%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248.
2026-10-28Markup$231.50+0.0%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248.
2026-10-21Markup$231.50+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markup$231.50+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markup$231.50+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$231.50+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markup$231.50+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markup$231.50+5.3%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markup$219.81+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markup$219.81-2.1%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
